Tetrahydromagnolol – (20601-85-8)

Magnolol, a bioactive lignan found in the bark of the Houpu magnolia (Magnolia officinalis) and Magnolia grandiflora, has garnered attention for its diverse pharmacological properties. This compound, which exists at levels of a few percent in magnolia bark, has been traditionally used in Chinese and Japanese medicine. Magnolol’s interaction with GABAA receptors in vitro and its antifungal properties highlight its potential as a therapeutic agent. Additionally, it exhibits osteoblast-stimulating and osteoclast-inhibiting activities, suggesting its use in anti-osteoporosis research. Studies have also demonstrated its efficacy in combating periodontal disease in rat models.

Magnolol’s chemical structure allows it to bind in a dimeric mode to PPARγ, acting as an agonist of this nuclear receptor. Furthermore, it may interact with cannabinoid receptors, showing partial agonist activity for CB2 receptors and lower affinity for CB1 receptors. These multifaceted interactions underscore its potential in various medical applications.

The compound’s structural analogues have been studied for their ability to modulate GABAA receptors, indicating a broader scope for its use in neurological conditions. As research continues, magnolol’s role in modern medicine is likely to expand, offering new avenues for treatment and prevention of various health conditions.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Magnolol
https://pubchem.ncbi.nlm.nih.gov/compound/5321851
https://www.sciencedirect.com/science/article/abs/pii/S0968089614007482